755752-82-0

Basic information

• Product Name: 1H-INDAZOLE-7-CARBOXYLIC ACID
• Synonyms: 7-INDAZOLE CARBOXYLLIC ACID;Methyl indazole-7-carboxylate;1H-Indazole-7-carboxylic acid methyl ester;Methyl indazole-7-carboxy...;7-(Methoxycarbonyl)-1H-indazole;7-(1H)Indazole carboxylic acid Methyl ester
• CAS NO: 755752-82-0
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.17
• Product Categories: Indazoles
• Mol File: 755752-82-0.mol

Chemical Properties

• Boiling Point: 345.2 °C at 760 mmHg
• Flash Point: 162.6 °C
• Appearance: /
• Density: 1.324
• Vapor Pressure: 6.24E-05mmHg at 25°C
• Refractive Index: 1.648
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.93±0.40(Predicted)
• CAS DataBase Reference: 1H-INDAZOLE-7-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-INDAZOLE-7-CARBOXYLIC ACID(755752-82-0)
• EPA Substance Registry System: 1H-INDAZOLE-7-CARBOXYLIC ACID(755752-82-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 755752-82-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Indazole-7-carboxylic acid serves as a key starting material in the synthesis of bioactive molecules, utilized for its capacity to contribute to the development of new drug compounds. Its role in medicinal chemistry is pivotal, providing a foundation for the creation of molecules with potential therapeutic applications.
Used in Medicinal Chemistry Research:
As a building block in the design and synthesis of new pharmaceutical entities, 1H-Indazole-7-carboxylic acid is employed to explore its anti-cancer and anti-inflammatory properties. This application is driven by the compound's inherent ability to engage in chemical reactions that can yield molecules with significant biological activity, thereby expanding the scope of available treatments for various diseases.
Used in Drug Discovery:
1H-Indazole-7-carboxylic acid is leveraged in drug discovery processes to identify and optimize potential drug candidates. Its unique structure allows for the exploration of various chemical modifications, which can lead to the enhancement of pharmacological properties, such as potency, selectivity, and bioavailability.
Used in the Development of Pharmacological Tools:
1H-Indazole-7-carboxylic acid is also utilized in the creation of pharmacological tools, which are essential for understanding the mechanisms of disease and the actions of drugs. These tools can aid researchers in deciphering complex biological pathways and in validating novel therapeutic targets.

InChI:InChI=1/C9H8N2O2/c1-13-9(12)7-4-2-3-6-5-10-11-8(6)7/h2-5H,1H3,(H,10,11)

Upstream product

• 22223-49-0 methyl 2-amino-3-methylbenzoate 
• 37619-23-1 2-acetylamino-3-methyl-benzoic acid methyl ester 
• 95-53-4 o-toluidine 
• 1132-03-2 2-(hydroxyimino)-N-(2-methylphenyl)acetamide 
• 1127-59-9 7-methyl-1H-indole-2,3-dione 
• 4389-45-1 3-methylantranilic acid 
• 138229-59-1 3-formyl-2-nitrobenzoic acid methyl ester 
• 253120-49-9 methyl 2-amino-3-formylbenzoate 
• 5471-82-9 methyl 3-methyl-2-nitrobenzoate 
• 67-56-1 methanol 
• 677304-69-7 1H-indazole-7-carboxylic acid 

Downstream Products

• 952479-64-0 methyl 2-(4-formylphenyl)-2H-indazole-7-carboxylate 
• 677304-69-7 1H-indazole-7-carboxylic acid 
• 1092961-09-5 (1H-indazol-7-yl)methanol 
• 312746-72-8 1-H-indazole-7-carbaldehyde 
• 944899-03-0 3-iodo-1H-indazole-7-carbaldehyde 

Relevant articles and documents

Indazole ester compound and pharmaceutical application thereof

The invention provides an indazole ester compound and a pharmaceutical application thereof. Specifically provided is a compound represented by a formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an optical isomer thereof, or an isotope substitution form thereof. The compound can be used for effectively inhibiting the activity of SARS-CoV-2Mpro, and can be used for preparing an SARS-CoV-2Mpro inhibitor. The compound provided by the invention has a good application prospect in preparation of drugs for resisting novel coronavirus and drugs for preventing and/or treating novel coronavirus pneumonia.

Azacycle diketone compound and preparation method thereof (by machine translation)

The invention provides a azacyclodiketone compound which is characterized by being a compound represented by the following structure. The compound has inhibitory activity on cap-dependent endonuclease. (by machine translation)

Preparation method of niraparib tosilate monohydrate

The invention discloses a preparation method of a compound 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-formamide tosilate monohydrate. The method includes: carrying out Ulman reaction on 1H-indazole-7-methyl formate and (S)-3-(4-halogenophenyl)piperidine-1-tert-butyl formate to prepare 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-methyl formate, then under the conditions of ammonia gas and p-toluenesulfonic acid, preparing 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-formamide tosilate monohydrate. The invention aims to avoid the disadvantages of existing methods, shortens the preparation route, and provides the preparation method of the 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-formamide tosilate monohydrate with high chiral purity, and the method has the characteristics of mild reaction and easy operation.

A novel synthetic method for preparing an anticancer medicine Niraparib

A novel synthetic method for preparing an anticancer medicine Niraparib is disclosed. The method includes subjecting an initial raw material that is 3-formyl-2-nitrobenzoic acid to 2-site nitro reduction, diazotization, reduction, cyclization, substitution, isomer resolution, amidation, and BOC removing to obtain the optically pure Niraparib the purity of which is 97.51% or above. The method is simple, convenient, high in yield, low in loss, easy to operate, low in equipment requirement and suitable for industrial production.

Asymmetric Synthesis of Fused Polycyclic Indazoles through Aminocatalyzed Aza-Michael Addition/Intramolecular Cyclization

The first example of an asymmetric aminocatalyzed aza-Michael addition of 1H-indazole derivatives to α,β-unsaturated aldehydes is described. The iminium/enamine cascade process lies at the heart of our strategy, leading to enantioenriched fused polycyclic indazole architectures. Variations on both the α,β-unsaturated aldehydes and the indazole-7-carbaldehyde heterocycles were studied in order to broaden the scope of the transformation in synthetically interesting directions. The fused polycyclic indazoles exhibit fluorescence properties and can undergo synthetic transformations.

Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists

N-Benzyl substitution of phenethylamine 5-HT2A receptor agonists has dramatic effects on binding affinity, receptor selectivity and agonist activity. In this paper we examine how affinity for the 5-HT2A/2C receptors are influenced by N-benzyl substitution of 4-bromo-2,5-dimethoxyphenethylamine derivatives. Special attention is given to the 2′ and 3′-position of the N-benzyl as such compounds are known to be very potent. We found that substitutions in these positions are generally well tolerated. The 2′-position was further examined using a range of substituents to probe the hydrogen bonding requirements for optimal affinity and selectivity, and it was found that small changes in the ligands in this area had a profound effect on their affinities. Furthermore, two ligands that lack a 2′-benzyl substituent were also found to have high affinity contradicting previous held notions. Several high-affinity ligands were identified and assayed for functional activity at the 5-HT2A and 5-HT2C receptor, and they were generally found to be less efficacious agonists than previously reported N-benzyl phenethylamines.

SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.

INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention is directed to indole amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.

INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.